![A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy [Et randomiseret, dobbeltblindt, placebokontrolleret, verdensomspaendende, dosisbestemmende klinisk multicenterforsog i fase II med parallelle grupper med en bevis-for-effekt ledende kohorte, der vurderer sikkerhed, tolerance og effekt af MK-8457 + MTX til patienter med aktiv kronisk leddegigt pa trods af behandling med methotrexate].](https://storage.googleapis.com/pcf_sb_39_1613727931605803249/assets/images/Adis_logo.png "A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy [Et randomiseret, dobbeltblindt, placebokontrolleret, verdensomspaendende, dosisbestemmende klinisk multicenterforsog i fase II med parallelle grupper med en bevis-for-effekt ledende kohorte, der vurderer sikkerhed, tolerance og effekt af MK-8457 + MTX til patienter med aktiv kronisk leddegigt pa trods af behandling med methotrexate]."){kind=logo}
Trial Profile
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy [Et randomiseret, dobbeltblindt, placebokontrolleret, verdensomspaendende, dosisbestemmende klinisk multicenterforsog i fase II med parallelle grupper med en bevis-for-effekt ledende kohorte, der vurderer sikkerhed, tolerance og effekt af MK-8457 + MTX til patienter med aktiv kronisk leddegigt pa trods af behandling med methotrexate].
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs MK 8457 (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms AM2
- Sponsors Merck Sharp & Dohme Corp.
- 16 Aug 2016 This trial was completed in Germany (End Date:2 Sep 2013).
- 26 Mar 2014 According to the ClinicalTrials.gov record, status changed from recruiting to discontinued.
- 06 Dec 2012 Planned End Date changed from 1 Nov 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov.